Your browser doesn't support javascript.
loading
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
Juric, Dejan; de Bono, Johann S; LoRusso, Patricia M; Nemunaitis, John; Heath, Elisabeth I; Kwak, Eunice L; Macarulla Mercadé, Teresa; Geuna, Elena; Jose de Miguel-Luken, Maria; Patel, Chirag; Kuida, Keisuke; Sankoh, Serap; Westin, Eric H; Zohren, Fabian; Shou, Yaping; Tabernero, Josep.
Afiliación
  • Juric D; Massachusetts General Hospital, Boston, Massachusetts. juric.dejan@mgh.harvard.edu.
  • de Bono JS; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • LoRusso PM; Yale University, New Haven, Connecticut.
  • Nemunaitis J; Mary Crowley Cancer Research Center, Dallas, Texas.
  • Heath EI; Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
  • Kwak EL; Massachusetts General Hospital, Boston, Massachusetts.
  • Macarulla Mercadé T; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Geuna E; Investigative Clinical Oncology, Fondazione Del Piemonte Per L'Oncologia, Candiolo Cancer Institute, Candiolo, Italy.
  • Jose de Miguel-Luken M; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Patel C; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • Kuida K; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • Sankoh S; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • Westin EH; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • Zohren F; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • Shou Y; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Clin Cancer Res ; 23(17): 5015-5023, 2017 Sep 01.
Article en En | MEDLINE | ID: mdl-28490463
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Piridinas / Benzoxazoles / Morfolinas / Inhibidores de Proteínas Quinasas / Fosfatidilinositol 3-Quinasa Clase I / Imidazoles / Neoplasias Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Piridinas / Benzoxazoles / Morfolinas / Inhibidores de Proteínas Quinasas / Fosfatidilinositol 3-Quinasa Clase I / Imidazoles / Neoplasias Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article